access to health care
Expand access to health care.
Occurrences
Preserving evidence-based access to mifepristone, including when dispensed by mail or retail pharmacy, is necessary to mitigate the imminent harm facing members of the public. Women deserve access to mifepristone for reproductive health care, and all Americans deserve integrity in the congressionally mandated, evidence-based process for FDA’s drug regulatory decisions.
Women deserve access to mifepristone for reproductive health care, and all Americans deserve integrity in the congressionally mandated, evidence-based process for FDA’s drug regulatory decisions.
Evidence
Yesterday, more than 250 House and Senate Democrats... filed an amicus brief to the Supreme Court urging them to overturn a Fifth Circuit decision that would upend the FDA approval process and restrict access to mifepristone. ... the emergency stay is necessary to ensure that Louisiana is not able to deny medically appropriate care to patients far beyond the state’s borders.
The House GOP agenda: Nothing to lower costs. Nothing to protect healthcare. Nothing to keep communities safe. Everything to make billionaires even richer.
The current official homepage spotlights health care as an active issue, including a call to prevent premium hikes, a critique of Republican health care cuts, and a prompt for constituents to share their health care stories.
Clark led more than 250 House and Senate Democrats in an amicus filing urging the Supreme Court to preserve mifepristone access and FDA authority, a concrete same-term action aimed at protecting health care access.
The House Clerk records Roll Call 49 on H.R. 1319, the American Rescue Plan Act, as passed 219-212; Clark (MA), Democratic, Massachusetts, voted Yea.
Public Law 117-2 section 9661 is titled improving affordability by expanding premium assistance for consumers and set lower premium percentages for 2021 and 2022, including 0 percent up to 150 percent of poverty and 8.5 percent at 400 percent and higher.
Section 2601 appropriated $7.6 billion for community health centers and community care, with funds available for grants to federally qualified health centers and related health services and infrastructure.
Section 9814 created a temporary 5 percentage point FMAP increase for qualifying states that begin covering the ACA Medicaid expansion population for eight quarters.
The House Clerk records Roll Call 420 on H.R. 5376 as passed 220-207 on the motion to concur in the Senate amendment; Clark (MA), Democratic, Massachusetts, voted Yea.
Section 12001, titled improve affordability and reduce premium costs of health insurance for consumers, extended the enhanced premium tax credit rules through taxable years before January 1, 2026.
Section 11406 added Medicare Part D cost-sharing rules for covered insulin products; for plan years 2023 through 2025, a month's supply may not exceed $35.
Clark's office said she led more than 250 congressional Democrats in an amicus brief urging the Supreme Court to preserve mifepristone access and FDA authority.
Congress.gov lists H.R.3421, the Medicare for All Act, as a Health bill introduced May 17, 2023, with latest action on December 17, 2024, referred to the Subcommittee on Health and status Introduced.
Assessments
Clark, as a federal House member, voted for enacted laws that materially expanded or protected health care access during her term. The American Rescue Plan expanded ACA premium assistance, funded community health centers, and created Medicaid expansion incentives; the Inflation Reduction Act extended enhanced ACA subsidies and capped some Medicare insulin costs. Later advocacy on mifepristone and Medicare for All adds effort but is not needed for full credit because enacted federal provisions directly advanced the broad promise to expand access to health care.
Clark has documented same-term advocacy aimed at protecting and preserving access to health care, including leading a large amicus filing to defend mifepristone access and using her office to press health care access issues. That is meaningful effort toward the promise, but the evidence does not show a completed federal policy expansion, so the claim is only partially fulfilled.
Clark took concrete same-term action to protect and preserve access to health care, including leading or joining a major Supreme Court amicus effort concerning mifepristone access and FDA authority. However, the evidence shows advocacy and litigation support rather than a completed federal policy expansion of health care access attributable to her. The broad promise is therefore partially advanced but not fully delivered on this record.